This study tests whether giving ALXN2220 again can help people with a rare heart condition called transthyretin amyloid cardiomyopathy. About 35 people who already received the drug once will get a second round. Researchers will check heart function and safety over 48 weeks.
Phase: PHASE2 • Sponsor: Neurimmune AG • Aim: Disease control
Last updated May 07, 2026 18:41 UTC